Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chan, R.
Right arrow Articles by Kerr, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, R.
Right arrow Articles by Kerr, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:996-999, 2004
© 2004 European Society for Medical Oncology

Can we individualise chemotherapy for colorectal cancer?

R. Chan* and D. J. Kerr

Department of Clinical Pharmacology, University of Oxford, Oxford, UK

* Current address: Department of clinical oncology, University of Hong Kong, Hong Kong

The first 150 words of the full text of this article appear below.

Colorectal cancer (CRC) is one of the leading malignancies in the Western World, responsible for ~400 000 deaths each year [1Go, 2Go]. Despite radical surgery, more than half of CRC patients develop metastases, and palliative chemotherapy has been utilised to alleviate symptoms and prolong survival [3Go, 4Go]. The availability of newer and more efficacious agents over the last few years has seen an improvement in median overall survival in these patients, particularly when the three agents, 5-fluorouracil (5-FU), irinotecan and oxaliplatin, are all used at some stage in the clinical course [5Go–10Go].

Nonetheless, the success of chemotherapy is still far from perfect, as tumour response is only observed in ~50% of patients and at the expense of toxicities, which in most subjects are mild to moderate but for other patients may be unpredictable and severe. In this regard, cytotoxic treatment is unique in that . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Oncol PractHome page
K. M. Field, S. Kosmider, M. Jefford, M. Michael, R. Jennens, M. Green, and P. Gibbs
Chemotherapy Dosing Strategies in the Obese, Elderly, and Thin Patient: Results of a Nationwide Survey
J. Oncol. Pract, May 1, 2008; 4(3): 108 - 113.
[Abstract] [Full Text] [PDF]